Capital Fund Management S.A. Tg Therapeutics, Inc. Call Options Transaction History

Capital Fund Management S.A.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$17.21 - $25.28 $1.79 Million - $2.62 Million	-103,800 Reduced 24.46%	320,600 $7.5 Million
Q2 2024 Aug 13, 2024	SELL	$13.32 - $19.19 $511,488 - $736,896	-38,400 Reduced 8.3%	424,400 $7.55 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $8.87 Million - $14.5 Million	-681,300 Reduced 59.55%	462,800 $7.04 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $4.83 Million - $13.6 Million	723,100 Added 171.76%	1,144,100 $19.5 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $1.26 Million - $4.01 Million	151,300 Added 56.1%	421,000 $3.52 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $1.12 Million - $2.53 Million	72,400 Added 36.7%	269,700 $6.7 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $2.02 Million - $3.82 Million	197,300 New	197,300 $2.97 Million
Q4 2021 Feb 10, 2022	SELL	$15.2 - $35.51 $211,280 - $493,589	-13,900 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$21.78 - $40.45 $302,742 - $562,255	13,900 New	13,900 $462,000

338

87.7M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.68B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.